Argenx Shares Fall as Vyvgart's Myositis Market Potential Narrows
Belgium - Shares in Belgian biotech company Argenx dropped Wednesday after the potential commercial reach of its flagship drug Vyvgart for the rare disease myositis was reported to be smaller than previously anticipated, dealing a blow to shareholder value and the company's near-term growth outlook.
The development signals a setback for one of Belgium's most prominent biotechnology firms, which has positioned Vyvgart as a key growth driver. A reduced addressable patient population for a rare-disease therapy can significantly alter revenue projections, weighing on investor confidence and the company's pipeline valuation at a critical stage of the drug's commercial rollout.
Argenx, the Belgian biotech behind Vyvgart, had been expected to expand the drug's footprint across a range of rare conditions, making the myositis indication a closely watched opportunity. The news that the potential reach of the therapy in this indication is now considered smaller than anticipated prompted Wednesday's share price decline, reflecting market concern over the narrowed commercial ceiling for the treatment.
Further details are expected as the story develops
